08/02/2012 3:22 am Welcome to isteroids.com - BLOG

Saturday 28, Jan 2012

  Dianabol

Posted By

Dianabol is one of the most common oral steroids called Methandrostenolone. A derivative of testosterone, Dianabol is one of the most popular steroids and exhibits strong anabolic and moderate androgenic properties. Its easy usage and effectiveness is what makes this steroid widely accepted. Its chemical name is 17a-methyl-17b-hydroxy-1,4-androstadien-3-one 1-Dehydro-17 a methyltestosterone.

Dianabol, or D-bol as it is commonly addressed, is widely used because of its remarkable ability to build muscle strength in a relatively very short span of time. It also possesses a multifaceted approach in building the muscles without causing and loss of weight. The Methandrostenolone contained in Dianabol is its most active ingredient and acts in an ergogenic manner when orally administered.

Most common users of D-bol are athletes and particularly bodybuilders seeking maximum muscle mass within minimum time limits. Dianabol contains a powerful anabolic agent which upon entering the body, increases the synthesis of the proteins and also causes the retention of nitrogen in it. Increase in the levels of proteins helps in the balancing of nitrogen in the body which further aids in the development of adaptogenic properties in it. This allows the body to adapt according to increased workloads as well as fatigue.

Dianabol’s primary role is that it lets the acquired muscle protein in the body to stay. This anabolic drug is also known to show considerable growth in body insulin, a hormone produced in the liver. This creates a soothing effect in the body and users of this effective steroid are often seen talking about improved sleep, lower stress levels, better appetite and feeling of relaxation despite outside pressures. This is particularly the result of increased normalizing effect of Dianabol after the RNA synthesis during stress. However, in bodybuilders, it prevents the body from avoiding catabolic stress which helps them perform at a higher level and also recover fast after tedious training regime.

What makes D-bol so sought after is its ability to stimulate strength gain in the muscle in a very direct way. During phases of heavy physical and mental stress & irregular training and caloric retention, this anabolic steroid creates a temporary anabolic state which stops the breaking down of protein so that it releases amino acids in other muscles of the body, making them more intact and strong.

Despite being such a popular muscle-mass building steroid, Dianabol is not very often used in pre-contest cycles. This is particularly because it increasingly aromatizes to estrogen and causes high retention of fluid in the body. It is always advised to administer this anabolic drug in limited amount as high dosage over an extended period of time can strain the functioning of the liver. Some other apparent effects that might occur owing to heavy dosage such as 100mg per day are gynecomastia, acne, oily skin, testicular atrophy, deepening of the voice, hair loss, high blood pressure and loss of libido in some cases.

The dosage of Dianabol is variable. For men, it is advisable to start with 10mg per day which can be increased up to 25mg per day. Women wanting to take Dianabol with an intent to cut fat and gain muscle strength should start with 5mg per day and must not go beyond 10mg in a day.

The active life of this drug is about 3-5 hours. Since it is rapidly absorbed in the digestive juices in the stomach, it is best advised to take it with food and large amount of water to avoid abdominal cramps. The advanced testing systems nowadays can identify metabolites of Dianabol in the urine samples of the user, up to 4 weeks after the last dose is administered.

Being a popular drug, Dianabol is easily available. There are numerous sites on the internet which sell this steroid from where it can be ordered with or without a medical prescription. One should bear in mind that Dianabol is a highly potent drug and hence should be taken only under the supervision of a physician.

Tuesday 20, Dec 2011

  Lives of patients may be changed with new asthma drug

Posted By

Pressure is mounting on the NHS to widen the use of a “wonder” drug that could help hundreds of thousands of severe asthma sufferers.

Currently, most of the 250,000 UK patients who suffer from severe allergic asthma are prescribed powerful oral steroids.

From Thisislondon.co.uk:

Under guidance from the NHS drugs rationing body, only about 1,000 of the worst-afflicted are offered the “revolutionary” drug omalizumab, which is proven to work but costs £12,000 a year.

Now, a new study has shown that 64 per cent of severe asthma sufferers who took omalizumab over 12 months significantly reduced their dependence on oral steroids – and half were able to stop taking them altogether.

Richard Cull, 31, a medical student at St George’s Hospital in Tooting, told the Evening Standard: “I’ve had asthma all my life and spent a good deal of my childhood in and out of hospital.

Dr Robert Niven, co-author of the University of Manchester study, said: “Omalizumab costs £12,000 a year, compared with oral steroids which are next to nothing. But the costs to the NHS of managing the side-effects have never been calculated.

They cause patients to gain significant amounts of weight and eventually develop diabetes, cataracts and glaucoma. About half go on to suffer from osteoporosis and other suffer from depression, anxiety and even growth retardation. That has to be worth reducing.”

Friday 11, Nov 2011

  Severe asthma drug may spare patients of complications

Posted By

Experts have recently disclosed that half of patients treated with omalizumab were able to stop taking potentially harmful steroids and most needed them less often.

Health chiefs were urged by Asthma UK to consider offering the jabs to more people.

From Mirror.co.uk:

Spokeswoman Emily Humphreys said: “This medicine can be life-changing. It can help people reduce their dose of oral steroids, which we know have substantial side effects.”

Just 1,000 of the UK’s 250,000 severe asthma sufferers are thought to receive the £12,000-a-year fortnightly injections, which go under the trade name Xolair.

Dr Rob Niven, of the University Hospital of South Manchester, added: “People with severe asthma live in fear of the next potentially fatal attack. Any research that supports an option that reduces the additional side effect burden of steroids is encouraging.”

Saturday 05, Nov 2011

  Vitamin D deficiency caused by oral steroids

Posted By

People on oral steroids are twice more likely to suffer from severe vitamin D deficiency than the general populace, according to a new research.

Doctors should get the vitamin D level of patients measured while prescribing steroids, as per Amy Skversky, assistant professor of pediatrics at Albert Einstein College of Medicine.

From Timesofindia.indiatimes.com:

Severe vitamin D deficiency is known to be linked with bone softening, rickets, and muscle weakness.

Steroids have been shown to cause vitamin D deficiency, possibly by increasing levels of an enzyme that inactivates the vitamin, according to an Einstein College statement.

Smaller studies involving people often prescribed steroids (children with asthma and patients with Crohn’s disease and lupus) have found significantly reduced vitamin D levels in them, reports the journal of Clinical Endocrinology and Metabolism.

The study on 31,000 children and adults disclosed that physicians should monitor vitamin D levels more diligently in patients being treated with oral steroids.

Thursday 07, Oct 2010

  Progression of Ocular Myasthenia Gravis can be stopped by steroids

Posted By

Progression of Ocular Myasthenia Gravis can be stopped by steroidsSteroids may help patients with myasthenia gravis (MG) to avoid the progression that begins in the eye muscles.

This finding was suggested by results from a retrospective analysis presented at the 135th Annual Meeting of the American Neurological Association (ANA).

From Docguide.com:

Of 110 patients with ocular MG, followed for at least 2 years, the 36% of patients who progressed during 2 years of follow-up were less likely to have used oral steroids, said co-author Iram Zaman, DO, Henry Ford Hospital, Detroit, Michigan, who presented the poster here on September 13. Half of the patients whose symptoms remained in the eyes used steroids, whereas 24% of patients progressed even though they took steroids (P = .013).

The presence of autoantibodies could be documented for 96 of the patients; 67% were shown to have had the antibodies for the acetylcholine receptor.

A dose analysis suggested a trend, with higher doses of steroids more likely to be associated with no progression. Doses were grouped for this analysis as <=20 mg/day, 20 to 40 mg/day, or >40 mg/day.

The higher doses used in patients reviewed by the investigators were the ones most likely to be associated with the disease remaining in the eyes. None of the 7 patients who used 50 or 60 mg of steroid generalised, Dr. Zaman noted, adding that 6 of these 7 patients received the doses within 7 months of symptom onset.

Dr. Zaman said that doctors make use of pyridostigmine or steroids, depending on their preferences, as there are no specific guidelines to recommend steroid use in the disease.

Thursday 19, Aug 2010

  Long term use of steroids effective in reducing risk of Lymphoma In Rheumatoid Arthritis

Posted By

Long term use of steroids effective in reducing risk of Lymphoma In Rheumatoid ArthritisAccording to data presented at EULAR 2007, the Annual European Congress of Rheumatology, in Barcelona, Spain, treatment with oral steroids for a period of two years or more can reduce the risk of rheumatoid arthritis (RA) related lymphoma.

It was disclosed that benefits of steroids were experienced regardless of when in the course of the disease the steroids were first administered.

From Sciencedaily.com:

The study involved 378 patients with rheumatoid arthritis-associated lymphoma identified from the Swedish Hospital Register and the Cancer Register compared with 378 individually matched RA controls, i.e. patients with RA but without lymphoma.

Using data on steroid treatment type and duration along with inflammatory load collected from cases and controls, information on lymphoma type (where observed) was also collected. The lymphoma tissues were obtained from the pathology laboratories and were reclassified according to the most recent lymphoma classification, the World Health Organization classification.

Interestingly, researchers also compiled information on the duration of RA at initiation of steroid treatment. In this study there was no correlation observed between protective function and length of RA at onset of steroidal treatment. The protective effect was identical in those starting steroid treatment the first five years after onset of RA and in those starting later (relative risk 0.6; 0.3-0.9). Steroid treatment outcome was not associated with the presence of the Epstein-Barr virus in the lymphomas.

Study author Dr Eva Baecklund of Uppsala University Hospital, Sweden said the data reveals a new aspect of steroid treatment.

Thursday 22, Jul 2010

  Oxidative stress research can be effective for treating rare health condition

Posted By

Oxidative stress research can be effective for treating rare health conditionResearchers at Queen Mary University London and the University of Leicester have announced a potential breakthrough to treat a rare, fatal medical complication that affects children and young people.

The preliminary data highlighting efficacy of the breakthrough was published as a letter in the New England Journal of Medicine and one patient has already been treated and experienced promising results as per scientists and clinicians from the two universities.

From Sciencedaily.com:

“Affected patients have episodes of bleeding in the lungs, which often need hospital admissions, and in some cases it can be life threatening. This is normally combated by the use of continuous oral steroids (which can have major side effects).

“In a child local to Leicester, we were able to show, for the first time, that there was high levels of oxidative stress in the lungs. In addition, we treated the increased oxidative stress by using of an antioxidant, N-acetyl cysteine – which has no side effects. Since she has been on this treatment she has had no lung bleeds, and the steroid dose has been significantly reduced.”

Dr Marcus Cooke, Senior lecturer in the Radiation and Oxidative Stress Section at the University of Leicester, added: “It is a really good feeling to be involved in a project looking at oxidative stress, that can make such an enormous difference to a person’s quality of life.

Idiopathic pulmonary haemosiderosis is a rare disease with an unknown cause, according to Jonathan Grigg, Professor of Paediatric Respiratory and Environmental Medicine at Queen Mary University London.

Wednesday 07, Jul 2010

  Potential oral drug for rheumatoid arthritis discovered

Posted By

Potential oral drug for rheumatoid arthritis discoveredCH-1504, considered by many as a potential oral drug for rheumatoid arthritis (RA), can motivate women to treat their condition earlier because it is less difficult than currently-available treatment options.

Chelsea Therapeutics, a pharmaceutical company specializing in treatment for rheumatoid arthritis and other immunological diseases, is currently on a developing spree to formulate an oral anti-inflammatory drug and conducting Phase I clinical trials in the UK with an aim to provide an amicable solution for this condition that is more prevalent in women and develops between ages of 35 and 50.

From News-Medical.Net:

Current treatment options for RA include over-the-counter oral nonsteroidal anti-inflammatory drugs (NSAIDs) and other pain relievers; oral steroids; but the gold standard for treatment is still methotrexate, a drug that been used for nearly 30 years. Newly available compounds known as biologic response modifiers, such as etanercept and infliximab are used when the disease progresses (mostly in combination with methotrexate) but have to be injected and are very expensive.

While methotrexate is often effective, long-term chronic doses of the drug can be toxic to the liver, kidneys and other organs. Short-term tolerability issues such as nausea, vomiting and diarrhea also often limit its use.

“Given the problems that many patients have tolerating methotrexate along with its long-term safety concerns, a drug candidate that is proven to be as effective or more effective than with fewer side effects would be a major breakthrough in the treatment of RA. This may prompt patients to treat their condition earlier and continue treatment longer,” says Dr. Pedder.

Dr. M. Gopal Nair, a professor and vice-chairman at the department of Biochemistry and Molecular Biology at the University of South Alabama, initially developed the CH-1504 therapy.

Tuesday 29, Jun 2010

  Asthma may effect black teens more than the whites

Posted By

Asthma may effect black teens more than the whitesBlack teenagers are more likely to develop steroid-resistant asthma than their white counterparts, according to a research conducted at the National Jewish Medical and Research Center.

It was disclosed in the study that black asthmatic teens are more likely to be sick and suffer from a higher mortality rate than white teens with asthma.

From News.Bio-Medicine.Org:

“Our results suggest that children with steroid-resistant asthma are more likely to be African-American, to have required treatment with oral steroids at an earlier age and to require larger amounts of oral steroids for only marginal control of their asthma,” said Joseph Spahn, M.D., a pediatric allergist and director of the Immunopharmacology Lab at National Jewish.

Other recent epidemiological studies have shown that blacks with asthma are sicker and have a higher mortality rate than whites with asthma. Doctors at National Jewish now are trying to determine whether blacks have a more vigorous immune response to airway inflammation–which means that higher doses of steroids must be used to control inflammation–or a poor response to steroids secondary to a genetic resistance to the drugs.

“The theory is that with ongoing airway inflammation you get worsening asthma and diminished steroid sensitivity,” Dr. Spahn said.

This study of 164 teen-agers treated at National Jewish also showed that 25 percent of the group was steroid resistant. Children with less than a 15 percent improvement in lung function following a “burst” of inhaled steroids–high doses over seven days–were considered steroid resistant.

“Twenty-five percent of the kids admitted to National Jewish have steroid-resistant asthma, which is much greater than anyone thought,” Dr. Spahn said.

African-American children are prone to steroid-resistant asthma, according to Joseph Spahn, M.D., a pediatric allergist and director of the Immunopharmacology Lab at National Jewish.

The study was published in the Journal of Allergy and Clinical Immunology.

Wednesday 16, Jun 2010

  Oxidative stress research inspires treatment for rare devastating condition

Posted By

Oxidative stress research inspires treatment for rare devastating conditionA potential breakthrough was announced by researchers at Queen Mary University London and the University of Leicester for treating Idiopathic pulmonary haemosiderosis, a rare but devastating disease with an unknown cause.

One patient affected with this devastating condition has already been treated by clinicians and scientists from the two universities and noticed promising results.

From Sciencedaily.com:

“Affected patients have episodes of bleeding in the lungs, which often need hospital admissions, and in some cases it can be life threatening. This is normally combated by the use of continuous oral steroids (which can have major side effects).

“In a child local to Leicester, we were able to show, for the first time, that there was high levels of oxidative stress in the lungs. In addition, we treated the increased oxidative stress by using of an antioxidant, N-acetyl cysteine - which has no side effects. Since she has been on this treatment she has had no lung bleeds, and the steroid dose has been significantly reduced.”

Dr Marcus Cooke, Senior lecturer in the Radiation and Oxidative Stress Section at the University of Leicester, added: “It is a really good feeling to be involved in a project looking at oxidative stress, that can make such an enormous difference to a person’s quality of life.

Preliminary data was published as a letter in the New England Journal of Medicine.

Next »